Pipeline
Lead Program
Plixorafenib Program
Our lead program focuses on plixorafenib, an investigational, next-generation BRAF inhibitor identified by our platform for its ability to inhibit a wide range of BRAF gene alterations in cancer cells beyond those targeted by earlier-generation BRAF inhibitors.
Building our pipeline
We focus primarily on compounds that have passed phase 1 trials and are proven to be safe, for which the main challenge is pinpointing which patient populations they will benefit most. We also consider pre-IND compounds where the biology is well understood and clinical trials are within sight.
We continue to consider licensing opportunities. To discuss a potential collaboration, please contact our business development team at: oib.e1722065004rof@r1722065004entra1722065004p1722065004.